Zobrazeno 1 - 10
of 97
pro vyhledávání: '"Jayaprakasam, Bolleddula"'
Autor:
Jayaprakasam Bolleddula, Sathej Gopalakrishnan, Ping Hu, Jennifer Dong, Karthik Venkatakrishnan
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 9, Pp 2075-2095 (2022)
Abstract N‐Nitrosamine (NA) impurities are considered genotoxic and have gained attention due to the recall of several marketed drug products associated with higher‐than‐permitted limits of these impurities. Rifampicin is an index inducer of mu
Externí odkaz:
https://doaj.org/article/7efd76f66d784d01a12fbf678e7c59af
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 6, Pp 577-588 (2021)
Abstract Ivosidenib is a potent, targeted, orally active, small‐molecule inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) that has been approved in the United States for the treatment of adults with newly diagnosed acute myeloid leukemia (AML)
Externí odkaz:
https://doaj.org/article/f873790105954979af8371d4169d979c
Autor:
Jayaprakasam Bolleddula, Sathej Gopalakrishnan, Ping Hu, Jennifer Dong, Karthik Venkatakrishnan
Publikováno v:
Clinical and Translational Science. 15:2075-2095
N-Nitrosamine (NA) impurities are considered genotoxic and have gained attention due to the recall of several marketed drug products associated with higher-than-permitted limits of these impurities. Rifampicin is an index inducer of multiple cytochro
Autor:
Jayaprakasam Bolleddula, Hao Chen, Lawrence Cohen, Xiaofei Zhou, Sandeepraj Pusalkar, Allison Berger, Farhad Sedarati, Karthik Venkatakrishnan, Swapan K. Chowdhury
Publikováno v:
Drug Metabolism and Disposition. 50:989-997
Autor:
O. Petter Veiby, Jennifer Fretland, Mark G. Qian, Jayaprakasam Bolleddula, Robbie Robertson, Maria Borland, Melissa Saylor Landen, Cindy Q. Xia, Andy Zhu, Secil Koseoglu, Kurt Eng, Afrand Kamali, Bradley Stringer, Thomas A. Keating, Katharine C. Lai, Michael D. Smith, Michelle L. Ganno, Bret M. Bannerman, Melissa Gallery, Donna Cvet, Adnan O. Abu-Yousif
Guanylyl cyclase C (GCC) is a unique therapeutic target with expression restricted to the apical side of epithelial cell tight junctions thought to be only accessible by intravenously administered agents on malignant tissues where GCC expression is a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e7d56b0bf0e605a39ee70fc897c8b59
https://doi.org/10.1158/1535-7163.c.6542328.v1
https://doi.org/10.1158/1535-7163.c.6542328.v1
Autor:
O. Petter Veiby, Jennifer Fretland, Mark G. Qian, Jayaprakasam Bolleddula, Robbie Robertson, Maria Borland, Melissa Saylor Landen, Cindy Q. Xia, Andy Zhu, Secil Koseoglu, Kurt Eng, Afrand Kamali, Bradley Stringer, Thomas A. Keating, Katharine C. Lai, Michael D. Smith, Michelle L. Ganno, Bret M. Bannerman, Melissa Gallery, Donna Cvet, Adnan O. Abu-Yousif
Supplemental Figure 1: heavy and light chain sequences for 5F9, the human IgG1 monoclonal antibody (mAb) targeting the extracellular domain of GCC as described previously Supplemental Figure 2: Characterization of TAK-164 and chKTI-DGN549 by A) SDS P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fc671e1a3ed72f6591ec22f46838181
https://doi.org/10.1158/1535-7163.22519161.v1
https://doi.org/10.1158/1535-7163.22519161.v1
Autor:
Tamara D. Cabalu, Mengyao Li, Kenichi Umehara, Dermot F. McGinnity, Neil Parrott, Kunal S Taskar, Arian Emami Riedmaier, Micaela B Reddy, Hugues Chanteux, Martin E. Dowty, Justine Badée, Jialin Mao, Jayaprakasam Bolleddula, Loeckie de Zwart, Jessica Rehmel, Dwaipayan Mukherjee, Chandra Prakash, Niresh Hariparsad, Masakatsu Kotsuma, Diane Ramsden, Karthik Venkatakrishnan, Venkatesh Pilla Reddy, Kushal Shah
Publikováno v:
Clinical Pharmacology & Therapeutics. 112:770-781
The International Consortium for Innovation and Quality (IQ) Physiologically Based Pharmacokinetic (PBPK) Modeling Induction Working Group (IWG) conducted a survey across participating companies around general strategies for PBPK modeling of inductio
Autor:
Claire C. Villette, Frances Brightman, Nathalie Dupuy, Astrid Zimmermann, Florianne Lignet, Frank T. Zenke, Nadia Terranova, Jayaprakasam Bolleddula, Samer El Bawab, Christophe Chassagnole
Publikováno v:
Cancer Research. 83:5699-5699
Introduction: Poly (ADP-ribose) polymerase (PARP) and ataxia telangiectasia and Rad3-related (ATR) inhibitors target key DNA damage response (DDR) kinases. PARP inhibitors (PARPi) suppress the catalytic activity of PARP and trap PARP in a complex wit
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 6, Pp 577-588 (2021)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology
Ivosidenib is a potent, targeted, orally active, small‐molecule inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) that has been approved in the United States for the treatment of adults with newly diagnosed acute myeloid leukemia (AML) who are
Autor:
Jayaprakasam, Bolleddula, Yang, Nan, Wen, Ming-Chun, Wang, Rong, Goldfarb, Joseph, Sampson, Hugh, Li, Xiu-Min
Publikováno v:
In Journal of Integrative Medicine May 2013 11(3):195-205